Ciltacabtagene autoleucel Recruiting Phase 3 Trials for Multiple Myeloma (MM) Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Recruiting | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy |